Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab

BACKGROUND: Nivolumab is approved for the treatment of refractory metastatic renal cell carcinoma. Patterns and predictors of progressive disease (PD) on nivolumab, and outcomes in such patients are lacking. METHODS: A retrospective analysis of patients (pts) with metastatic clear cell renal cell ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Zahoor, Haris, Barata, Pedro C., Jia, Xuefei, Martin, Allison, Allman, Kimberly D., Wood, Laura S., Gilligan, Timothy D., Grivas, Petros, Ornstein, Moshe C., Garcia, Jorge A., Rini, Brian I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192175/
https://www.ncbi.nlm.nih.gov/pubmed/30333065
http://dx.doi.org/10.1186/s40425-018-0425-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192175/
https://www.ncbi.nlm.nih.gov/pubmed/30333065
http://dx.doi.org/10.1186/s40425-018-0425-8

Ejemplares similares